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Abstnset Treatment of human neutrophils with tumor necrosis factor-a (I’NF-u) resulted in an increase in concentration of ceramide and its 
catabolite, sphingosine. Sphingosine, a potent endogenous protein kinase C (PKC) inhibitor, as well as TNF-a, induced intemucleosomal DNA 
fragmentation and morphological changes characteristic of apoptotic cells. &amide and sphingosine-l-phosphate, the initial product of sphingosine 
catabolism. did not cause anontosis under our experimental conditions. In addition, 1-(5isoquinolinesulfonyl)-2-methylpiperazine (H7) and N, N- 
dimethylsphingosine (DMS): known as PKC inhibitors, also induced apoptosis, suggesting that-induction of apoptosis by sphingosine may be related 
to inhibition of PKC activity. These results indicate that sphingosine deacylated from ceramide may be an endogenous modulator mediating apoptotic 
signals by TNF-a in neutrophils. 
Key words: Apoptosis; Sphmgosine; Tumor necrosis factor-a; Neutropbil 
1. Introduction 
Apoptosis is an active, energy-dependent process through 
which living cells participate in their own destruction [1,2]. 
Apoptosis provides a mechanism for removal of unwanted cells 
in a variety of situations including thymus involution, gut crypt 
epithelial cell turnover, and embryonic tissue remodeling. 
Aging neutrophils have also been shown to undergo apoptosis 
spontaneously [3,4]. Apoptotic senescent neutrophils are recog- 
nized and phagocytosed by macrophages. This process has 
been suggested to represent a mechanism in vivo to limit neu- 
trophil-mediated tissue injury in intlamed sites. 
Various cytokines released during inflammation regulate the 
survival of neutrophils in the lesion either by promoting or by 
inhibiting their death. InfIammatory mediators, such as en- 
dotoxic lipopolysaccharide, complement factor 5a, and gran- 
ulocyte-macrophage colony-stimulating factor, markedly in- 
hibited neutrophil apoptosis [S]. In contrast, TNF-a, a potent 
neutrophil activator [f&-8], has been shown to accelerate the rate 
of neutrophil apoptosis [9]. TNF-a responsive sphingomyelin 
hydrolysis and ceramide generation have been reported to be 
implicated in a signal transduction pathway that mediates in- 
duction of apoptosis by TNF-a in U-937 cells [ 10,111. Although 
the mechanism of action of ceramide in mediating apoptotic 
signals remains poorly understood, we recently found that 
sphingosine, a catabolite of ceramide, induced apoptosis in a 
variety of tumor cell lines including human leukemic HL-60 
cells @A. Sweeney et al., unpublished data). The present stud- 
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ies were undertaken to determine whether sphingolipids such 
as ceramide and sphingosine are involved in the intracellular 
signaling of apoptosis by TNF-a in neutrophils. 
2. Materials and methods 
2. I. Chemicals 
Sphingosine, N-octanoylsphingosine (Ca-ceramide), sphingosine-l- 
phosphate and DMS were synthesized as described previously [12-141. 
All sphingolipids were dissolved in ethanol. Control experiments were 
performed with ethanol (< 0.1%) as the vehicle. H7 was obtained from 
Calbiochem-Novabiochem Co. (San Diego, CA). Natural human TNF- 
a (5 x 10’ U/mg) was a gift from Otsuka Cellular Technology Int. 
(Tokushima, Japan). Ribonuclease-A, and bovine serum albumin 
(BSA, essentially fatty acid-free) were obtained from Sigma Chemical 
Co. (St. Louis, MO). [‘HIAcetic anhydride was from DuPont- New 
England Nuclear (Boston, MA). HPLC-grade chloroform and metha- 
nol, and thin-layer chromatography (TLC) plates were from EM Sepa- 
rations (Gibbstown, NJ). An autoradiography enhancer spray, Resolu- 
tion TLC, was from L.M. Corp. (Chestnut Hill, MA). 
2.2. Isolation of human neutrophils 
Heparinixed venous blood was obtained from healthy volunteers. 
Neutrophils were isolated by dextran sedimentation and centrifugation 
on a Ficoll-Paque (Pharmacia LKB, Uppsala, Sweden) cushion as pre- 
viously described [15]. After contaminating erythrocytes were removed 
by hypotonic lysis, cells were resuspended with RPM1 1640 containing 
0.1% BSA. Such processing yielded > 98% viable neutrophils, as deter- 
mined by Wright-Giemsa staining. 
2.3. Measurement of ceramide and sphingosine concentration 
Purified neutrophils (5 x 106/ml) were-treated with human TNF-a 
(3.000 U/ml) for the indicated times. and then linids were extracted from 
c&. For &amide measurement, ~lipid extracts were incubated with 
Escherichia coli diacylglycerol kinase as previously reported [16]. Cer- 
amide phosphate was then isolated by TLC and the ceramide mass was 
quantitated. Sphingosine concentrations were measured by conversion 
to N- [31-Ijacetylated sphingosine by acylation with [‘H]acetic anhydride 
[17]. After lipid extracts were treated by 0.1 N NaOH for 1 h, dried 
samples were dissolved in 40 ~1 of 0.008N NaOH in methanol/l0 mM 
solution of [HJacetic anhydride (1: 1). Acylation proceeded for 1 h at 
37°C. Following treatment of samples with NaOH, Nj3H]acetylated 
sphingosine was isolated by TLC and the sphingosine mass was quan- 
titated. 
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2.4. Analysis of DNA fragmentation 
DNA fragmentation was analyzed by using agarose gel electrophore- 
sis [18]. 5 x IO6 neutrophils were harvested, washed, and incubated in 
0.5 ml of 50 mM Tris-HCl, pH 8.0, containing 1mM EDTA, 0.25% 
Nonidet P-40 (Sigma) and 0.1% ribonuclease-A at 37°C for 30 min. 50 
~1 of 10 mg/ml proteinase-K (Boehringer, Mannheim, Germany) was 
then added and the incubation continued for an additional 30 min. 
After incubation, 0.1 ml of loading buffer (0.25% Bromophenol blue- 
0.25% xylene cyan01 FF-30% glycerol) was added. 25 ,& of the tube 
content was loaded into each well of the 2% agarose gels, and electro- 
phoresis was carried out at 10 V/cm. A HaeIII digest of ox174 DNA 
(New England Biolabs Inc., Beverly, MA) was applied to each gel to 
provide size markers of 1,353,1,078,872,603,3 10 bp, respectively. The 
DNA in gels was visualized under ultraviolet light after staining with 
ethidium bromide (Sigma). 
2.5. Assessment of neutrophil apoptosis by cytology 
For morphological assessments, neutrophils (5 x 106/ml) were treated 
with different agents. Cytocentrifuge slides were then prepared and 
stained with Wright-Giemsa stain. Cells were examined under oil im- 
mersion light microscopy, and apoptotic neutrophils were defined as 
cells containing one or more darkly stained pyknotic nuclei [3,5]. For 
assessment of the percentage of cells showing morphology of apoptosis, 
500 cells/ slide were counted. Viability by Trypan blue exclusion was 
also assessed. 
3.Results 
Fig. 1 demonstrates the effect of TNF-a on ceramide and 
sphingosine content in neutrophils. The cellular concentrations 
of ceramide increased by 68% (from 189 f 42 to 3 17 f 15 pmol/ 
lo6 cells) at 5 min after the addition of TNF-a (3,000 U/ml) 
(Fig. 1A). Ceramide concentrations in neutrophils incubated at 
37°C in the absence of TNF-a were unchanged. Under the 
same conditions, TNF-a induced an increase in sphingosine 
content. Sphingosine concentrations increased by 95% (from 
9.1 + 0.2 to 17.7 f 3.4 pmol/106 cells) at 1 h after the addition 
of TNF-a (Fig. 1B). The increase occurred continuously over 
1 h. Sphingosine concentrations in neutrophils incubated at 
37°C for 1 h in the absence of TNF-a increased by only 29% 
(from 9.1 f 0.2 to 11.8 + 1.7 pmol/106 cells). Thus, treatment 
of neutrophils with TNF-a caused an increase of both ceramide 
and sphingosine concentrations. 
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As previously reported [9], agarose gel electrophoresis of 
DNA from neutrophils treated for 6 h with TNF-a (3,000 U/ml) 
showed DNA fragmentation with a pattern characteristic of 
internucleosomal fragmentation (Fig. 2). DNA from neutro- 
phils treated with an ejhanol vehicle, cell-permeable C,-cer- 
amide (15 PM), or sphmgosine-l-phosphate (15 ,uM) was un- 
fragmented. However, sphingosine (15 ,uM), as well as H7 (50 
PM) and DMS (15 PM), caused internucleosomal DNA frag- 
mentation. The effects of sphingosine were first detected after 
2 h and increased with longer treatment (data not shown). 
Induction of apoptosis by TNF-a had previously been con- 
firmed by ultrastructural examination [9]. Light microscopy of 
neutrophils treated for 6 h with TNF-a (3,000 U/ml) or sphin- 
gosine (15 PM) showed that many neutrophils exhibited mor- 
phologic features of apoptosis, such as one or more darkly 
stained pyknotic nuclei and cytoplasm vacuolation (Fig. 3). 
There was no evidence of significant necrotic cell death (as- 
sessed by the ability of neutrophils to exclude Trypan blue) in 
culture. Isolated neutrophils have been known to undergo ap- 
optosis spontaneously [3-51. The percentage of apoptotic cells 
in neutrophils treated with an ethanol vehicle increased from 
0 + 0 to 1.1 f 0.5% at 6 h. The percentages of apoptosis in 
neutrophils treated for 6 h with TNF-a (3,000 U/ml), sphingo- 
sine (15pM), DMS (15pM), and H7 (50pM) were 31.1 + 3.3, 
27.7 + 3.0, 33.1 + 4.1, and 27.6 + 3.0%, respectively (Fig. 4A). 
Treatment with sphingosine induced apoptosis in a dose-de- 
pendent manner. The time course study showed that the pro- 
portion of neutrophils demonstrating morphological features 
of apoptosis increased progressively with time after addition of 
TNF-a (3,000 U/ml) or sphingosine (15 PM) (Fig. 4B). 
4. Discussion 
TNF-a had the capacity to induce or accelerate apoptosis of 
neutrophils as previously reported [9]. One physiological func- 
tion of TNF-a, which primes many neutrophil functions includ- 
ing the respiratory burst [6-81, may be the acceleration of apop- 
tosis of primed neutrophils to limit neutrophil-mediated tissue 
injury. Previous studies showed that TNF-a signaling involved 
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Fig. 1. Effects of TNF-a on ceramide and sphingosine concentrations in neutrophils. Neutrophils were incubated at 37°C in the presence (0) or absence 
(0) of 3,000 U/ml TNF-a. Cellular lipids were extracted at the indicated times and concentrations of ceramide (A) and sphingosine (B) were measured 
as described in section 2. 
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Fig. 2. Agarose gel electrophoresis of DNA from neutrophils treated 
with different agents. Neutrophils were treated for 6 h with an ethanol 
vehicle (Con), 3,000 U/ml TNF-a, 15 PM C,-ceramide (Cer), 15 PM 
sphingosine (Sph), 15pM sphingosine-l-phosphate (S-l-P), 50pM H7, 
and 15 PM DMS. DNA was isolated from neutrophils and analyzed 
by 2.0% agarose gel electrophoresis as described in section 2. The first 
lane is a HaeIII digest of ox174 DNA. 
sphingomyelin hydrolysis to ceramide by activation of sphin- 
gomyelinase [ 19,201. In addition, treatment with exogenously 
added sphingomyelinase has been shown to cause an increase 
in concentration of sphingosine deacylated from ceramide, sug- 
gesting that sphingomyelinase and ceramidase functioned 
cooperatively [21]. In this study we found that treatment of 
neutrophils with TNF-a resulted in an increase in cellular con- 
centration of both ceramide and sphingosine. The increase of 
ceramide content was more rapid than that of sphingosine 
content. These findings suggest hat the increase of sphingosine 
content results from degradation of formed ceramide after 
TNF-a treatment. 
Ceramide has been reported to initiate apoptosis [lO,ll]. 
Although cerarnide-activated protein kinase and phosphatase 
have been described in some cells [22-241, the mechanism of 
action of ceramide in mediating apoptotic signaling remains 
obscure. In neutrophils, sphingosine (5-15 ,uM), as well as 
Fig. 3. Morphologic appearance of neutrophils treated for 6 h with an 
ethanol vehicle (A), 3,000 U/ml TNF-a (B), and 15 PM sphingosine (C). 
The cells were stained by Wright-Giemsa stain as described in section 
2. Treatment with TNF-a or sphingosine induced apoptotic changes 
such as one or more darkly stained pyknotic nuclei and cytoplasm 
vacuolation. Original magnification: x 700. 
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Fig. 4. (A) The percentage of apoptotic cells (assessed morphologically) 
of neutrouhils treated for 6 h with an ethanol vehicle (Con). 3.000 U/ml 
TNF-a, $10 and 15 PM sphingosine (Sph) and 15 PM DMS: (B) Time 
course of apoptosis of neutrophils incubated in the presence of an 
ethanol vehicle (0), 3,000 U/ml TNF-a (m), or 15 PM sphingosine (0). 
The values represent the average of three separate determinations 
(& S.E.M.). 
TNF-a, was capable of inducing apoptosis. However, the same 
concentrations of ceramide or sphingosine- 1 -phosphate did not 
induce apoptosis. Sphingosine has been shown to inhibit PKC 
in vitro and in cells [25-271. In addition, H7 and DMS, known 
as PKC inhibitors, also induced apoptosis. Induction of apop- 
tosis by sphingosine may be related to inhibition of PKC activ- 
ity (unpublished results by H. Ohta et al). On the other hand, 
sphingosine has been shown to activate protein kinases, which 
were distinct from PKC, cyclic nucleotide-activated kinases, 
and calcium-dependent kinases, with high specificity for 
n-erythro-sphingosine [28], although the involvement of sphin- 
gosine-dependent protein kinase in processes of apoptosis 
remains to be examined. An increase (8.6 pmoY106 cells) of 
sphingosine at 1 h after treatment with TNF-a was similar in 
magnitude to the transient increase in diacylglycerol that oc- 
curred upon N-formyl-methionyl-leucyl-phenylalanine (fMLP) 
stimulation of neutrophils (about 6 pmol/106 cells) [29]. More- 
over, this increase was estimated to correspond to that by ex- 
posure to about 10-20 PM sphingosine sufficient to induce 
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apoptosis. On the other hand, ceramide concentration is very 
high (about 200 PM) in the unstimulated human neutrophils 
and the addition of exogenous cell permeable ceramide (C-8 
ceramide,up to 20 PM) did not induce apoptosis of neutrophils 
incubated in medium containing 0.1% BSA. These findings 
suggest hat sphingosine deacylated from ceramide, not cer- 
amide itself, may function as an endogenous modulator mediat- 
ing induction of apoptosis by TNF-a in neutrophils. 
Sphingosine and its methylated derivative, DMS, showed 
inhibitory effects on in vitro as well as in vivo tumor cell growth 
[30,31]. We recently found that induction of apoptosis by sphin- 
gosine and DMS was found in many tumor cell lines including 
human leukemic HL-60 cells, Co10 205 colon tumor cells, and 
A431 epidermoid carcinoma cells (EA. Sweeney et al., unpub- 
lished data). In most tumor cell types, DMS was a stronger 
inducer of apoptosis than sphingosine. DMS has been detected 
in A431 epidermoid carcinoma cells [32] and murine ILZ-de- 
pendent T lymphocyte CTLL cells [33]. However, changes in 
the levels of DMS and its participation in signaling pathways 
have not been evaluated, because of the difficulty of quantifica- 
tion of its mass levels in cells. 
Acknowledgements: The authors thank Stephen Anderson, Ph.D., and 
Jennifer Stoeck for scientiiic editing and preparation of the manuscript. 
This study was supported by funds from The Biomembrane Institute, 
in part under a research contract with Otsuka Pharmaceutical Co., and 
by National Cancer Institute Outstanding Investigator Grant CA42505 
(to S.H.). 
References 
[l] Wyllie, A.H., Kerr, J.F.R. andcurrie, A.R. (1980) Int. Rev. Cytol. 
68,25 l-306. 
[2] Gerschenson, L.E. and Rotello, R.J. (1992) FASEB J. 6, 245& 
2455. 
[3] Savill, J.S, Wyllie, A.H., Henson, J.E., Walport, M.J., Henson, 
P.M. and Haslett, C. (1989) J. Clin. Invest. 83, 865875. 
[4] Savill, J., Dransfield, I., Hogg, N. and Haslett, C. (1990) Nature 
343, 170-173. 
[5] Lee, A., Whyte, M.K.B. and Haslett, C. (1993) J. Leuko. Biol. 54, 
283-288. 
[6] Shalaby, M.R., Aggarwal, B.B., Rinderknecht, E., Svedersky, 
L.P., Finkle, B.S. and Palladino Jr., M.A. (1985) J. Immunol. 135, 
2069-2073. 
[7l Gamble, J.R., Harlan, J.M., Klebanoff, S.J. and Vadas, M.A. 
(1985) Proc. Natl. Acad. Sci. USA 82, 8667-8671. 
[8] Schleiffenbaum, B. and Fehr, J. (1990) J. Clin. Invest. 86,184-195. 
[9] Takeda, Y., Watanabe, H., Yonehara, S., Yamashita, T., Saito, S. 
and Sendo, F. (1993) Int. Immunol. 5, 691-694. 
[lOI 
[ill 
WI 
1131 
v41 
v51 
WI 
[I71 
Obeid, L.M., Linardic, C.M., Karolak, L.A. and Hannun, Y.A. 
(1993) Science 259, 1769-1771. 
Jarvis, W.D., Kolesnick, R.N., Fomari, F.A., Traylor, R.S., 
Gewirtz, D.A. and Grant, S. (1994) Proc. Natl. Acad. Sci. USA 
91,73-77. 
Igarashi, Y., Hakomori, S., Toyokuni, T., Dean, B., Fujita, S., 
Sugimoto, M., Ogawa, T., El-Ghendy, K. and Racker, E. (1989) 
Biodtochemistry 28, 6796-6800. 
Vunnam, R.R. and Radin, N.S. (1979) B&him. Biophvs. Acta _ _ _ 
573, 73-82. 
Ruan, F., Sadahira, Y., Hakomori, S. and Igarashi, Y. (1979) 
Bioorg. Med. Chem. Lett. 2. 973-978. 
Kimu&, S., Kawa, S., R.uan, F., Nisar, M., Sadahira, Y., 
Hakomori, S. and Igarashi, Y. (1992) B&hem. Pharmacol. 44, 
1585-1595. 
Okazaki, T., Bielawska, A., Bell, R.M. and Hannun, Y.A. (1990) 
J. Biol. Chem. 265, 15823-15831. 
Ohm, H., Ruan, F., Hakomori, S., Igarashi, Y. (1994) Anal. Bio- ,. 
them. [m press). 
[18] Gorczyca, W., Gong, J., Ardelt, B., Traganos, F. and Darzynk- 
iewicz; Z. (1993) Cancer Res. 53, 31863192. 
1191 Dressler. K.A.. Mathias. S. and Kolesnick. R.N. (1992) Science 27. . * 
1715-1718. ’ ’ 
\ I 
[20] Heller, R.A. and Kronke, M. (1994) J. Cell Biol. 126, 5-9. 
[21] Slife, C.W., Wang, E., Hunter, R., Wang, S., Burgess, C., Liotta, 
D.C. and Merrill Jr., A.H. (1989) J. Biol. Chem. 264,10371-10377. 
[22] Math&, S., Dressler, K.A. and Kolesnick, R.N. (1991) Proc. Natl. 
Acad. Sci. USA 88, 10009-10013. 
[23] Lozano, J., Berm, E., Municio, M.M., Diaz-Meco, M.T., 
Dominguez, I., Sanz, L. and Moscat, J. (1994) J. Biol. Chem. 269, 
19200- 19202. 
[24] Dobrowsky, R.T. and Hannun, Y.A. (1993) Adv. Lipid Res. 25, 
91-104. 
[25] Hammn, Y.A., Loomis, C.R., Merrill Jr., A.H. and Bell, R.M. 
(1986) J. Biol. Chem. 261, 12604-12609. 
[26] Merrill, A.H., Jr., Sereni, A.M., Stevens, V.L., Hannun, Y.A., 
Bell, R.M. and Kinkade Jr., J.M. (1986) J. Biol. Chem. 261,1261& 
12615. 
[271 Hammn, Y.A. and Bell, R.M. (1989) Science 243, 500-507. 
[28] Pushkareva, M.Y., Khan, W.A., Alessenko, A.V., Sahyoun, N. 
and Hannun, Y.A. (1992) J. Biol. Chem. 267, 1524615251. 
[29] Honeycutt, P.J. and Niedel, J.E. (1986) J. Biol. Chem. 261, 15900- 
15905. 
[30] Endo, K., Igarashi, Y., Nisar, M., Zhou, Q. and Hakomori, S. 
(1991) Cancer Res. 51, 1613-1618. 
[31] Okoshi, H., Hakomori, S., Nisar, M., Zhou, Q., Kimura, S., 
Tashiro, K. and Igarashi, Y. (1991) Cancer Res. 51, 60196024. 
[32] Igarashi, Y., Kita&ra, K., Toyokuni, T., Dean, B., Fenderson, 
B.. Oaawa. T. and Hakomori. S. (1990) J. Biol. Chem. 265.5385- 
[33] Felding-Habermann, B., Igarashi, Y., Fenderson, B.A., Park, 
L.S., Radin, N.S., Inokuchi, J., Strassmann, G., Handa, K. and 
Hakomori, S. (1990) Biochemistry 29, 63146322. 
